Table 2.

Type of migraine treatment dispensed within 60 days following the entry in the incident migraine cohort

Migraine treatment	Incident migraine cohort
	Total	Males	Females	P value
	N=4457 (%)	N=1393 (%)	N=3064 (%)
Treatment typology				<0.001
Acute*	3613 (81.1)	1121 (80.5)	2492 (81.3)
Specific acute treatment†
Triptans (sumatriptan, zolmitriptan, rizatriptan, almotriptan, eletriptan, frovatriptan)	1915 (53.0)	567 (50.6)	1348 (54.1)
Non-specific acute treatment†
Antiemetics (ondansetron)	9 (0.2)	5 (0.4)	4 (0.2)
Aspirin	5 (0.1)	1 (0.1)	4 (0.2)
Drugs for functional gastrointestinal disorders (metoclopramide)	12 (0.3)	4 (0.4)	8 (0.3)
NSAIDs (diclofenac, flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolac, naproxen, nimesulide, piroxicam)	1136 (31.4)	380 (33.9)	756 (30.3)
Opioids (tramadol, codeine/paracetamol)	61 (1.7)	17 (1.5)	44 (1.8)
More than one specific/non-specific acute medication†	475 (13.1)	147 (13.1)	328 (13.2)
Prophylactic*	477 (10.7)	159 (11.4)	318 (10.4)
Specific prophylactic treatment‡
Antiserotonin agents (pizotifen)	95 (19.9)	28 (17.6)	67 (21.1)
Non-specific prophylactic treatment‡
Antidepressants (amitriptyline, mirtazapine)	89 (18.7)	17 (10.7)	72 (22.6)
Beta-blockers (metoprolol, propranolol)	40 (8.4)	19 (11.9)	21 (6.6)
Other anticonvulsants (valproic acid, lamotrigine)	151 (31.7)	76 (47.8)	75 (23.6)
Antiepileptics (topiramate)	83 (17.4)	16 (10.1)	67 (21.1)
More than one specific/non-specific prophylactic medication‡	19 (4.0)	3 (1.9)	16 (5.0)
Both acute and prophylactic medication*	367 (8.2)	113 (8.1)	254 (8.3)

*The percentage was calculated on the total of treated patients.

†The percentage was calculated on the total of patients received acute treatment.

‡The percentage was calculated on the total of patients received prophylactic treatment.

NSAIDs, Non-Steroidal Anti-inflammatory Drugs.